6579-27-7

Basic information

• Product Name: 2,6-DICHLORO-N-HYDROXYBENZENECARBOXIMIDOYL CHLORIDE
• Synonyms: 2,6-DICHLORO-N-HYDROXYBENZENECARBOXIMIDOYL CHLORIDE;ALPHA,2,6-TRICHLOROBENZALDOXIME, TECH.;2,6-DICHLORO-N-HYDROXYBENZENECARBOXIMIDOYL CHLOR;2,6-Dichloro-n-hydroxybenzenecarboximidoyl chlorid;2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride , Tech.;alpha-Chloro-2,6-dichlorobenzaldoxime;2,6-Dichlorobenzenehydroximic acid chloride;2,6-Dichlorobenzohydroxamoyl chloride
• CAS NO: 6579-27-7
• Molecular Formula: C₇H₄Cl₃NO
• Molecular Weight: 224.47
• Mol File: 6579-27-7.mol
• Article Data: 62

Chemical Properties

• Melting Point: 85 °C
• Boiling Point: 349.187 °C at 760 mmHg
• Flash Point: 164.983 °C
• Appearance: /
• Density: 1.53
• Vapor Pressure: 1.79E-05mmHg at 25°C
• Refractive Index: 1.597
• PKA: 9.77±0.70(Predicted)
• CAS DataBase Reference: 2,6-DICHLORO-N-HYDROXYBENZENECARBOXIMIDOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLORO-N-HYDROXYBENZENECARBOXIMIDOYL CHLORIDE(6579-27-7)
• EPA Substance Registry System: 2,6-DICHLORO-N-HYDROXYBENZENECARBOXIMIDOYL CHLORIDE(6579-27-7)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 6579-27-7(Hazardous Substances Data)

Usage

General Description

2,6-Dichloro-n-hydroxybenzenecarboximidoyl chloride, also known as dihydroxydichlorobenzimidoyl chloride, is a chemical compound with the molecular formula C7H4Cl2N2O2. It is a chlorinated derivative of benzenecarboximidoyl chloride and is used in the synthesis of various pharmaceuticals and other organic compounds. 2,6-Dichloro-n-hydroxybenzenecarboximidoyl chloride is a white to light brown powder with a molecular weight of 224.03 g/mol. 2,6-Dichloro-n-hydroxybenzenecarboximidoyl chloride is also used as an intermediate in the production of dyes and pigments, as well as in the manufacture of some specialty chemicals. It is important to handle this compound with caution, as it can be harmful if swallowed, inhaled, or absorbed through the skin, and it may cause irritation to the respiratory system, skin, and eyes.

InChI:InChI=1/C7H4Cl3NO/c8-4-2-1-3-5(9)6(4)7(10)11-12/h1-3,12H

Upstream product

• 25185-95-9 2,6-dichlorobenzaldoxime 
• 3714-77-0 2,6-dichlorobenzaldoxime 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 

Downstream Products

• 129144-32-7 methyl 3-(2,6-dichlorophenyl)-4-acetylisoxazole-5-carboxylate 
• 122247-13-6 3-(2,6-Dichloro-phenyl)-4-(4-nitro-phenyl)-5-trifluoromethyl-isoxazole 
• 122247-06-7 3-(2,6-Dichloro-phenyl)-5-(4-nitro-phenyl)-4-trifluoromethyl-isoxazole 
• 129144-37-2 5-Acetyl-3-(2,6-dichloro-phenyl)-isoxazole-4-carboxylic acid ethyl ester 
• 129144-35-0 4-Acetyl-3-(2,6-dichloro-phenyl)-isoxazole-5-carboxylic acid ethyl ester 
• 129144-33-8 4-Benzoyl-3-(2,6-dichloro-phenyl)-isoxazole-5-carboxylic acid methyl ester 
• 129144-36-1 3-(2,6-Dichloro-phenyl)-5-propionyl-isoxazole-4-carboxylic acid methyl ester 
• 129144-34-9 3-(2,6-Dichloro-phenyl)-4-propionyl-isoxazole-5-carboxylic acid methyl ester 
• 122247-14-7 4-(4-Chloro-phenyl)-3-(2,6-dichloro-phenyl)-5-trifluoromethyl-isoxazole 
• 122247-07-8 5-(4-Chloro-phenyl)-3-(2,6-dichloro-phenyl)-4-trifluoromethyl-isoxazole 
• 122247-15-8 3-(2,6-Dichloro-phenyl)-4-(4-methoxy-phenyl)-5-trifluoromethyl-isoxazole 
• 122247-08-9 3-(2,6-Dichloro-phenyl)-5-(4-methoxy-phenyl)-4-trifluoromethyl-isoxazole 

Relevant articles and documents

Discovery of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen-induced hepatotoxicity

Acetaminophen (APAP) overdose is a leading cause of acute hepatic failure and liver transplantation, while the existing treatments are poorly effective. Therefore, it is necessary to develop effective therapeutic drugs for APAP-induced hepatotoxicity. Farnesoid X receptor (FXR) is a potential target for the treatment of liver disease, and the activation of FXR protects mice against APAP-induced hepatotoxicity. Compound 5, a glycine-conjugated derivative of FXR agonist 4, was designed to extend the chemical space of existing FXR agonists. Molecular modeling study indicated that compound 5 formed hydrogen bond network with key residues of FXR. Moreover, compound 5 (10?mg/kg) revealed better protective effects against APAP-induced hepatotoxicity than parent compound 4 (30?mg/kg). Further mechanical research indicated that compound 5 regulated the expressions of genes related to FXR and oxidative stress. These findings suggest that compound 5 is a promising FXR agonist suitable for further research, and it is the first time to verify that the glycine-conjugated derivative five exerted better protective effects than its parent compound.

BENZISOXAZOLE COMPOUND

The present invention provides a compound, a salt thereof, or a prodrug thereof as a compound effective for preventing and/or treating fibrosis, the compound being represented by formula (1) (wherein A is an optionally substituted benzene ring; B is optionally substituted aryl or optionally substituted heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom; ------ of -----Y is a single or double bond when Y is a carbon atom, or ------ of -----Y is a single bond when Y is a nitrogen atom; each R1 independently represents lower alkyl, or two R1s may be bound to each other to form a spiro ring or a crosslinked structure, or two R1s may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y; p is 0, 1, or 2; or (R1)p is oxo) .

PPARs-FXR multi-target micromolecular agonist as well as preparation method and application thereof

The invention discloses a PPARs-FXR multi-target micromolecule agonist and a preparation method and application thereof, the structure is shown in a general formula I, and the definition of each substituent group is shown in the description and claims. Th